The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries

Autor:	Caballero, T, Aberer, W, Longhurst, H J, Maurer, M, Zanichelli, A, Perrin, A, Bouillet, L, Andresen, I
Rok vydání:	2017
Předmět:	Europe Male Treatment Outcome Bradykinin B2 Receptor Antagonists Angioedemas Hereditary Humans Female Registries Bradykinin Retrospective Studies
Zdroj:	Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid
Popis:	Hereditary angioedema (HAE) due to C1-inhibitor deficiency (C1-INH-HAE) is a rare, potentially fatal, bradykinin-mediated disease. Icatibant is a bradykinin B2 receptor antagonist originally approved in 2008 in the European Union and 2011 in the United States as an acute therapy option for HAE attacks in adults.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::5f7214d862bae1ab85d4c838d5d269ca https://hdl.handle.net/20.500.12530/32154 Zobrazit plný text záznamu